Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):224-6. doi: 10.1136/jnnp-2014-310287. Epub 2015 Jan 27.

Authors

R Hoepner¹, P Klotz¹, S Faissner¹, R Schneider¹, M Kinner¹, C Prehn¹, R Gold¹, A Chan¹

Affiliation

¹ Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.

PMID: 25628377
DOI: 10.1136/jnnp-2014-310287

No abstract available

Keywords: MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; VIROLOGY.

Publication types

Letter

MeSH terms

Adult
Cognition Disorders / etiology
Cognition Disorders / psychology
Early Diagnosis
Female
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / diagnosis
Leukoencephalopathy, Progressive Multifocal / psychology*
Male
Memory
Middle Aged
Multiple Sclerosis / complications
Multiple Sclerosis / drug therapy
Multiple Sclerosis / psychology
Natalizumab / adverse effects*
Natalizumab / therapeutic use
Neuropsychological Tests
Psychomotor Performance
ROC Curve
Retrospective Studies

Substances

Immunosuppressive Agents
Natalizumab